Company profile: PTS Diagnostics
1.1 - Company Overview
Company description
- Provider of point-of-care diagnostic devices and supplies delivering lipid, glucose, and A1C results from small blood samples, including CardioChek Plus and CardioChek PA analyzers, A1CNow+, CardioChek Home Cholesterol Test System, PTS Panels test strips, and PTS Collect capillary tubes.
Products and services
- CardioChek Plus: A point-of-care analyzer that delivers lipid and glucose results from a small blood sample in about 90 seconds, suitable for point-of-care testing
- A1CNow+: A fingerstick-based system that produces quick A1C results from a fingerstick blood sample, useful for diabetes management
- CardioChek PA: A lab-quality analyzer that offers lipid panel results from a small blood sample in as little as 90 seconds
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to PTS Diagnostics
Fractyl Health
HQ: United States
Website
- Description: Provider of curative therapies for metabolic diseases, including Revita, a therapy designed to modify duodenal dysfunction via hydrothermal ablation to restore metabolic health, and Rejuva, a preclinical AAV gene therapy platform aimed at improving islet function for long-term remission of T2D and obesity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fractyl Health company profile →
Animas
HQ: United States
Website
- Description: Provider of external insulin pumps for people with diabetes, designing, developing, manufacturing, and selling these devices. Believed to be the second-largest supplier in the U.S. by new pump placements. Introduced the R1000 in July 2000 and expects to begin shipping its third-generation pump.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Animas company profile →
Intarcia
HQ: United States
Website
- Description: Provider of long-term therapies for chronic diseases, offering the MEDICITM Drug Delivery System for twice-yearly subcutaneous osmotic implants, ITCA 650 (twice-yearly exenatide implant) for type 2 diabetes, and an Ionic Liquid Platform converting injectable biologics and peptides into oral therapies; pipeline includes i2o-105s (long-acting GLP-1 receptor agonist), i2o-107 (long-acting amylin), and i2o-110 (dual agonist) for type 2 diabetes, obesity, and NASH.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intarcia company profile →
Biodel
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics for the treatment of diabetes, focused on developing and commercializing diabetes treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biodel company profile →
Modulim
HQ: United States
Website
- Description: Provider of light-based imaging and care management solutions: Clarifi Imaging System, a non-contact, noninvasive tool using spatial frequency domain imaging to assess microvascular health by measuring tissue oxygenation and perfusion; LAMP, integrating patient assessment, data management, and care coordination; Modulim Cloud, a HIPAA-compliant platform for secure data and imaging; and Magnifi Software for tailored views and remote care collaboration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Modulim company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for PTS Diagnostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to PTS Diagnostics
2.2 - Growth funds investing in similar companies to PTS Diagnostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for PTS Diagnostics
4.2 - Public trading comparable groups for PTS Diagnostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →